One-third of chemo drugs used off-label; China to cut drug wholesalers in reform move;

@FiercePharma: Chinese government plans to cut the number of drug wholesalers to 3K from 13K. Pharma stocks there rose on the news. More | Follow @FiercePharma

@EricPFierce: Gilead, Teva now making nice over Viread patent, ending years of litigation. News | Follow @EricPFierce

@AlisonBFierce: HealthMap has expanded its reach, allowing people to search for any of 11 vaccines available near their home. Story | Follow @AlisonBFierce

> Almost one-third of chemotherapy drugs are used off-label, a study found; 14% for uses supported by the National Comprehensive Care Network and 10% for uses without FDA or NCCN approval. Report

> The Chinese government plans to cut the number of drug wholesalers to 3,000 from 13,000, in a move that could help support pharma profits. Report

> A new European patent court specializing in pharma and life sciences is expected to be operational in 2015 under a newly finalized agreement. Report

> The FDA warned doctors not to use codeine in children who've undergone surgery to remove their tonsils or adenoids. Report

> A lack of new drugs for childhood cancers has stalled the increase in 5-year survival rates. Report

> Pfizer ($PFE) tapped Leo Burnett Worldwide to launch its over-the-counter version of Nexium, licensed from AstraZeneca ($AZN), which sells the branded version. Report

Medical Device News

 @FierceMedDev: Dune gains CE mark for next gen-breast cancer Dx tool. News | Follow @FierceMedDev

 @MarkHFierce: Hmm, the second med device venture funding in two days. This time, a focus on uterine fibroid ablation. Release | Follow @MarkHFierce

 @DamianFierce: Thanks to investor excitement, Life Technologies might now be too pricey for a sale. More | Follow @DamianFierce

> Natera launches prenatal diagnostic with big Quest co-sign. Story

> Medtronic halves estimate of device tax hit. Item

Biotech News

 @FierceBiotech: If you missed it yesterday, check out @RyanMFierce's feature on FierceBiotechIT.com : Top 10 Biotech Techies, 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Interesting biotech model: NC development team nabs $5M angel tranche for their latest biotech play. Story | Follow @JohnCFierce

> Chelsea rebounds after FDA agrees to take a look at new Northera data. News

> Star-crossed Merck reorganizes troubled biosimilars effort around Samsung pact. Report

> MDxHealth hits testing milestone with prostate cancer epigenetic Dx. Item

Drug Delivery News

> Lentigen's stem cell delivery for brain tumors nets FDA orphan status. News

> PolyActiva seeks drug partner for new intraocular delivery implant. Report

> Oramed presses forward into PhII with oral insulin pill. Story

> EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand. Item

Biomarkers News

> NIH pours $900K into Parkinson's biomarker research. News

> Alzheimer's biomarkers indicate dementia advancement. More

> Mayo study spotlights new biomarkers for quick kidney injury alert. Report

> NYU investigative team on the trail of PTSD biomarkers. Article

> Nanomix plans test of triple biomarker heart attack Dx. Story

And Finally... The extraordinary science of addictive junk food. Report (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.